Skip to main content
UTHR $586.70 -0.76%
UTHR logo
UTHR · UNITED THERAPEUTICS Corp
Track UTHR — free
Market Cap
$25.18B
Shares
42.59M
Volume · Nov 16 170.67K Avg daily vol (3M) 700.23K
All webcasts

Earnings call · FY2026 Q3

UNITED THERAPEUTICS Corp (UTHR) Q3 2026 Earnings Call

Concluded Nov 4, 2026
Nov 4, 2026
Period
FY2026 Q3
Runtime
—
Sources
3 artifacts
Revenue $832.50M +4.1% YoY
Diluted EPS $5.71 -20.3% YoY
Gross margin 88.1% +0.7 pp YoY
Net income $258.60M -23.6% YoY
Open full screen Slides 28 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 4, 2026
United Therapeutics reported $832.5 million in revenue for the quarter ended September 30, 2026, versus $799.5 million, while net income declined to $258.6 million from $338.7 million.
10-Q report · filed Nov 4, 2026
United Therapeutics said Liquidia must remove PH-ILD from Yutrepia’s label after an adverse patent ruling and agreed to pay $330.4 million for past and future damages; Nebulized Tyvaso’s IPF application has an FDA goal date of April 26, 2027.

The audio replay and transcript follow the call.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · regions

United States$808.50M +4.3% YoY
Non Us$24.00M -2.8% YoY

Capital returned

Buybacks · derived
$500.00M
Shares repurchased
980,394
Full-screen source Call document